Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin.

Lorza AMArias, Ravi H, Philip RC, et al. "Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin." Sci Rep. 2020;10(1):14449.